The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase I trial to determine the maximum tolerated dose and evaluate the safety and pharmacokinetics (PK) of docetaxel-PNP, polymeric nanoparticle formulation of docetaxel, in subjects with advanced solid malignancies.
Kyung Hae Jung
No relevant relationships to disclose
Kyu-Pyo Kim
No relevant relationships to disclose
Dok Hyun Yoon
No relevant relationships to disclose
Yong Sang Hong
No relevant relationships to disclose
Chang-Min Choi
No relevant relationships to disclose
Jin-Hee Ahn
No relevant relationships to disclose
Dae Ho Lee
No relevant relationships to disclose
Jae-Lyun Lee
No relevant relationships to disclose
Min-Hee Ryu
No relevant relationships to disclose
Baek-Yeol Ryoo
No relevant relationships to disclose
Heung-Moon Chang
No relevant relationships to disclose
Tae Won Kim
No relevant relationships to disclose
Sung-Bae Kim
No relevant relationships to disclose
Sang-We Kim
No relevant relationships to disclose
Cheolwon Suh
No relevant relationships to disclose
Yoon-Koo Kang
No relevant relationships to disclose
Jungsin Lee
No relevant relationships to disclose
Kyun-Seop Bae
No relevant relationships to disclose
Yong-Man Kim
No relevant relationships to disclose